Cancer cell procoagulants and their pharmacological modulation

Haemostasis
M B Donati, N Semeraro

Abstract

Cancer cells may promote fibrin formation in the tumor microenvironment through availability of procoagulant activities which are mainly of two types: tissue thromboplastin-like or direct activator of coagulation factor X. The pharmacological modulation of these activities could be potentially important in the control of metastasis growth. However, very limited information is available so far on this issue; it has recently been shown that the direct activator of coagulation factor X is a vitamin K-dependent activity which is depressed by warfarin treatment, not by anticoagulation with heparin or defibrinating enzymes. Whether the inhibition of this peculiar cancer procoagulant is involved in the antimetastatic activity of warfarin is a stimulating hypothesis which needs to be further substantiated.

Citations

Dec 1, 1988·In Vitro Cellular & Developmental Biology : Journal of the Tissue Culture Association·L CuratoloN Semeraro
Nov 1, 1988·Thrombosis Research·J L FrancisI Taylor
Dec 1, 1993·British Journal of Haematology·M Amirkhosravi, J L Francis
Nov 1, 1991·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·B Nakstad, T Lyberg
Sep 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicole M KudererCharles W Francis
Feb 15, 1990·International Journal of Cancer. Journal International Du Cancer·N SemeraroM Colucci
Jul 1, 1987·Thrombosis Research·M J Auger, M J Mackie
Dec 1, 1987·The British Journal of Surgery·R DoverJ L Francis
Sep 1, 1993·Baillière's Clinical Haematology·A PoggiM B Donati
Jun 15, 1987·International Journal of Cancer. Journal International Du Cancer·A FalangaM B Donati
Apr 15, 1986·International Journal of Cancer. Journal International Du Cancer·N SemeraroF Carpagnano
May 15, 1986·International Journal of Cancer. Journal International Du Cancer·C L GeczyD Goldstein
Apr 22, 2006·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·J J NegusA T Cohen
Dec 3, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Emanuela NapoleoneRoberto Lorenzet
Aug 16, 2011·Thrombosis Research·Emanuela NapoleoneRoberto Lorenzet
Feb 8, 2006·Journal of Thrombosis and Haemostasis : JTH·C RossiA Poggi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.